Table 2.
Grade ≥ 3 TEAEs
| AE | Zanubrutinib (n = 41) |
|---|---|
| Patients with ≥1 grade ≥ 3 TEAE | 20 (48.8) |
| Infections and infestations | 6 (14.6) |
| Pneumonia | 2 (4.9) |
| Abdominal infection | 1 (2.4) |
| Herpes zoster | 1 (2.4) |
| Lung infection | 1 (2.4) |
| Otitis media chronic | 1 (2.4) |
| Urinary tract infection | 1 (2.4) |
| Laboratory investigations | 5 (12.2) |
| Decreased neutrophil count | 3 (7.3) |
| Increased alanine aminotransferase increased | 1 (2.4) |
| Increased γ-glutamyl transferase | 1 (2.4) |
| Decreased platelet count | 1 (2.4) |
| Decreased white blood cell count | 1 (2.4) |
| General disorders and administration site conditions | 3 (7.3) |
| Death | 2 (4.9) |
| Gait inability | 1 (2.4) |
| Musculoskeletal and connective tissue disorders | 3 (7.3) |
| Back pain | 1 (2.4) |
| Bone pain | 1 (2.4) |
| Synovitis | 1 (2.4) |
| Gastrointestinal disorders | 2 (4.9) |
| Abdominal pain | 2 (4.9) |
| Metabolism and nutrition disorders | 2 (4.9) |
| Hypokalemia | 1 (2.4) |
| Metabolic acidosis | 1 (2.4) |
| Blood and lymphatic system disorders | 1 (2.4) |
| Anemia | 1 (2.4) |
| Ear and labyrinth disorders | 1 (2.4) |
| Sudden hearing loss | 1 (2.4) |
| Eye disorders | 1 (2.4) |
| Cataract | 1 (2.4) |
| Hepatobiliary disorders | 1 (2.4) |
| Liver injury | 1 (2.4) |
| Renal and urinary disorders | 1 (2.4) |
| Proteinuria | 1 (2.4) |
All data are n (%).